DISEASE CHARACTERISTICS:

• Diagnosis of 1 of the following hematologic malignancies:

  • Aggressive non-Hodgkin's lymphoma (NHL), including, but not limited to, diffuse large B-cell NHL, meeting 1 of the following criteria:

    • Failed prior autologous hematopoietic stem cell transplantation (HSCT)
    • Not eligible for autologous HSCT or conventional myeloablative HSCT

  • Low-grade NHL

    • Achieved complete remission (CR) that lasted < 6 months after completion of prior conventional therapy

  • Mantle cell NHL

    • First CR allowed

  • Chronic lymphocytic lymphoma, meeting both of the following criteria:

    • Failed 2 lines of prior conventional therapy
    • Refractory to fludarabine, defined as failure to achieve a complete or partial response after treatment with a fludarabine-containing regimen (or another nucleoside analog [e.g., cladribine or pentostatin]) OR relapse within 12 months after completion of a fludarabine-containing regimen (or another nucleoside analog)

  • Hodgkin's lymphoma, meeting both of the following criteria:

    • Failed prior front-line therapy
    • Failed OR not eligible for autologous HSCT

  • Multiple myeloma, meeting 1 of the following criteria:

    • Received prior chemotherapy
    • Failed autografting

  • Acute myeloid leukemia

    • Must have < 5% marrow blasts at the time of study transplantation
    • No circulating leukemic blasts in the peripheral blood

  • Acute lymphoblastic leukemia

    • Must have < 5% blasts at the time of study transplantation
    • No circulating leukemic blasts in the peripheral blood

  • Chronic myelogenous leukemia

    • Beyond first chronic phase allowed provided patients received prior myelosuppressive chemotherapy or HSCT AND has < 5% marrow blasts at the time of study transplantation
    • No circulating leukemic blasts in the peripheral blood

  • Myelodysplastic syndromes or myeloproliferative diseases, meeting both of the following criteria:

    • Failed prior myelosuppressive chemotherapy or HSCT
    • Must have < 5% marrow blasts at the time of study transplantation

  • Waldenstrom Macroglobulinemia

    • Must have failed 2 courses of therapy

• Disease treatable by HSCT

  • Refused or not eligible for treatment on a conventional transplantation protocol
  • Autologous HSCT is not a treatment option
• Disease expected to be stable without chemotherapy for ≥ 100 days
• No CNS involvement with disease refractory to intrathecal chemotherapy

• Related or unrelated donor available

  • Matched for ≥ 1 HLA-DRB1 allele AND 1 HLA-DQB1 allele
  • No 10/10 HLA-A, -B, -C, -D, -DRB1, or -DQB1 matched unrelated donor available
  • Disease likely to progress during HLA typing
  • No marrow donors
  • Crossmatch negative NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.

PATIENT CHARACTERISTICS:

Age

• Under 75

Performance status

• Lansky 70-100% (for pediatric patients) OR
• Karnofsky 70-100% (for adult patients)

Life expectancy

• Not severely limited by diseases other than malignancy

Hematopoietic

• Not specified

Hepatic

• No cirrhosis of the liver with evidence of portal hypertension
• No alcoholic hepatitis
• No fulminant liver failure
• No chronic viral hepatitis with bilirubin > 3 mg/dL
• No ascites related to portal hypertension
• No esophageal varices
• No history of bleeding esophageal varices
• No hepatic encephalopathy
• No uncorrectable hepatic synthetic dysfunction evidenced by prolongation of PT
• No bacterial or fungal liver abscess
• No symptomatic biliary disease
• No biliary obstruction

Renal

• Not specified

Cardiovascular

• No symptomatic coronary artery disease
• Ejection fraction ≥ 35% (required for patients with a history of taking anthracyclines or cardiac disease)
• No other cardiac failure requiring therapy
• No poorly controlled hypertension despite use of multiple antihypertensive drugs

Pulmonary

• DLCO ≥ 35%
• No requirement for supplementary continuous oxygen
• Total lung capactiy ≥ 35%
• FEV_1 ≥ 35%

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for up to 12 months after completion of study treatment
• HIV negative
• No other disease that would severely limit life expectancy

• No active non-hematologic malignancy within the past 5 years except nonmelanoma skin cancer

  • No more than 20% risk of disease recurrence from prior non-hematologic malignancy
• No fungal infection with radiological progression after receiving amphotericin B or active triazole for > 1 month

PRIOR CONCURRENT THERAPY:

Biologic therapy

• See Disease Characteristics

Chemotherapy

• See Disease Characteristics
• More than 3 weeks since prior intensive cytotoxic chemotherapy for cytoreduction except hydroxyurea or imatinib mesylate

Endocrine therapy

• Not specified

Radiotherapy

• Not specified

Surgery

• Not specified